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A B S T R A C T   
Many organisms, ranging from plants to mammals, contain phospholipase A2 enzymes (PLA2s), which catalyze the production of lysophospholipids and fatty acid 
proinflammatory mediators. PLA2s are also common constituents of animal venoms, including bees, scorpions and snakes, and they cause a wide variety of toxic 
effects including neuro-, myo-, cyto-, and cardio-toxicity, anticoagulation and edema. The aim of this study was to develop a generic method for profiling enzy-
matically active PLA2s in snake venoms after chromatographic separation. For this, low-volume high-throughput assays for assessment of enzymatic PLA2 activity 
were evaluated and optimized. Subsequently, the assays were incorporated into a nanofractionation platform that combines high-resolution fractionation of crude 
venoms by liquid chromatography (LC) with bioassaying in 384-well plate format, and parallel mass spectrometric (MS) detection for toxin identification. The 
miniaturized assays developed are based on absorbance or fluorescence detection (respectively, using cresol red or fluorescein as pH indicators) to monitor the pH 
drop associated with free fatty acid formation by enzymatically active PLA2s. The methodology was demonstrated for assessment of PLA2 activity profiles of venoms 
from the snake species Bothrops asper, Echis carinatus, Echis coloratus, Echis ocellatus, Oxyuranus scutellatus and Daboia russelii russelii.   
1. Introduction 
Phospholipase A2 (PLA2, EC 3.1.1.4) is a common enzyme occurring 
in many organisms, ranging from plants to mammals (Murakami et al., 
2011). PLA2s are crucial enzymes in lipid metabolism and lipid-protein 
interactions. They also play a significant role in various cellular pro-
cesses such as biotransformation and digestion of phospholipids, signal 
transduction and host defense (Dennis et al., 2011). PLA2s are connected 
to human pathophysiological events and associated with certain types of 
cancers, arthritis, and inflammatory disorders, and therefore have been 
studied extensively (Brglez et al., 2014; Murakami et al., 2014; Yarla 
et al., 2015). 
PLA2s are also widely distributed in animal venoms. Snake venom 
PLA2s (svPLA2s) can be major toxin components – they often comprise 
30–71% of the total venom proteins, and they can also be diverse in 
terms of amino acid composition, as evidenced by the UniProtKB data-
base containing over 400 unique svPLA2s (Tasoulis and Isbister, 2017). 
In addition to catalyzing the production of lysophospholipids and fatty 
acid pro-inflammatory mediators, svPLA2s are multifunctional enzymes 
and cause a wide variety of toxic effects ranging from neurotoxicity, 
myotoxicity, anticoagulant effects, cytotoxicity, cardiotoxicity, to 
edema (Ferraz et al., 2019). Because of the pathological consequences of 
these toxins to prey and snakebite victims, svPLA2s have been exten-
sively investigated (Ferraz et al., 2019; Panfoli et al., 2010). Since May 
2018, snake envenoming has been categorized as one of the most 
neglected tropical diseases (World Health Organization, 2018). The 
annual number of human snakebites is estimated to be between 1.8 and 
2.7 million worldwide, resulting in 81,000–138,000 deaths and around 
three times more cases of permanent morbidity (Guti�errez et al., 2017). 
Many victims receive inadequate treatment or no treatment at all. The 
World Health Organization (WHO) has therefore adopted a resolution 
towards tackling this devastating global health problem (Guti�errez et al., 
2017). 
Snake venoms are complex biochemical mixtures that are injected 
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via the fangs of snakes for killing prey and for defense. These venoms 
comprise many different pathological proteins and peptides, and other 
organic molecules. Venom composition is typically complex (50–200 
proteins per species) and highly variable, with often extensive inter- 
specific, and even, intra-specific venom variations observed (Casewell 
et al., 2014; Haney et al., 2019). Rooted in the latter are geographical 
differences, living habitat, sex, and age of a snake, thereby increasing 
venom complexity even more (Calvete, 2019; Gopalakrishnakone and 
Calvete, 2016). Consequently, antivenom therapies, which are based on 
antibodies produced in horses or sheep following their immunization 
with venom or mixtures of venoms, are highly specific to those venoms 
used for production, but often lack efficacy for treating snakebites by 
other snake species (Casewell et al., 2014). In recent years, research 
efforts have increased on the potential utility of small molecule drugs as 
potential alternatives for conventional antivenom therapies. These 
promising approaches focus on neutralizing entire classes of venom 
enzymes, irrespective of sequence and structural variation, with small 
molecular inhibitors or metal chelators. For instance, recent studies 
have demonstrated that enzyme inhibitors and metal chelating agents, 
such as EDTA and DMPS, are capable of neutralizing snake venom 
metalloproteinase toxins in pre-clinical models of envenoming (Ains-
worth et al., 2018; Albulescu et al., 2019). In relation to svPLA2s, a 
number of studies have explored the neutralizing potential of the generic 
PLA2 inhibitors methyl-varespladib and varespladib (Lewin et al., 2016). 
These compounds show great promise for the future development of 
affordable, stable and broad-spectrum treatment for PLA2-induced tox-
icities following snake envenoming. However, as svPLA2s are important 
venom toxins responsible for a diverse array of severe pathologies 
following envenoming, the development of analytics for rapid svPLA2 
profiling after chromatographic separation of snake venoms – the 
approach described in this study - is an essential prerequisite for efficient 
selection and in vitro validation of novel PLA2 inhibiting agents. 
Assays using chromogenic molecules for PLA2 profiling have previ-
ously been developed (Petrovic et al., 2001; Sharko and Kisel, 2011). 
One of these assays relies on hydrolysis of a substrate by PLA2s into a 
coloured product, with ensuing absorbance measured at 425 nm, as 
described by Petrovic et al. (2001) In addition, both radioactivity based 
assays (Aufenanger et al., 1993; Katsumata et al., 1986) and fluorogenic 
assays (Darrow et al., 2011; Mitnaul et al., 2007) have been described. 
All these assay formats, however, are probe substrate dependent and 
thus dependent on the selectivity and enzymatic activity of each PLA2 
for the probe substrate used. Assays for assessment of generic enzymatic 
PLA2 activity use a phospholipid as a generic substrate, in combination 
with pH indicators to measure medium acidification upon phospholipid 
hydrolysis (Camacho-Ruiz et al., 2015; Price, 2007; Sutto-Ortiz et al., 
2017). This enzymatic reaction involves PLA2s cleaving the sn-2 ester of 
phospholipids, generating a free fatty acid and a lyso-phosholipid. Price 
et al. and Lobo De Araújo et al. measured PLA2 activity of crude snake 
venoms using the pH indicators bromothymol blue (Price, 2007) and 
phenol red (de Araújo and Radvanyi, 1987), respectively. These assays 
were performed in cuvettes, using a spectrophotometer, or in 96-well 
format. The use of bromothymol blue in a PLA2 assay was considered 
for this study, but was abandoned since literature reports this pH indi-
cator to be able to inhibit phospholipase subunits under certain condi-
tions (de Araújo and Radvanyi, 1987). 
In this study, two assays for enzymatic PLA2 activity were developed 
in 384-well format. One assay makes use of cresol red with colorimetric 
readout whereas the other uses fluorescein with fluorescence readout. 
The assays were optimized and validated for application in a workflow 
comprising high-resolution chromatographic fractionation of snake 
venoms followed by enzymatic PLA2 bioassaying. For this, well plates 
with collected fractions were vacuum-centrifuged to dryness followed 
by robotic pipetting of bioassay reagents and plate reader based readout 
in order to assess PLA2 activities. The feasibility and usefulness of the 
approach for measuring generic svPLA2 activity profiles was demon-
strated using medically relevant snake venoms from Bothrops asper, Echis 
carinatus, Echis coloratus, Echis ocellatus, Oxyuranus scutellatus and 
Daboia russelii russelii. 
2. Materials and methods 
2.1. Chemicals and biological reagents 
Water was purified with a Milli-Q Plus system (Millipore, Amster-
dam, The Netherlands). DMSO was supplied by Riedel-de-Ha€en 
(Zwijndrecht, The Netherlands). Acetonitrile (ACN; ULC/MS grade) and 
formic acid (FA) were obtained from Biosolve (Valkenswaard, The 
Netherlands). All salts used for buffer preparation were of analytical 
grade and purchased from Merck (Kenilworth, USA), Fluka (Bucharest, 
Romania) or Sigma-Aldrich (Darmstadt, Germany). Micro-90® concen-
trated cleaning solution was supplied by Sigma-Aldrich. Lyophilised 
snake venoms (see Table 1) were provided by the Centre for Snakebite 
Research & Interventions (Liverpool School of Tropical Medicine, UK) 
and stored long-term at   80 �C. Stock solutions of crude venoms (5.0 
mg/mL) were prepared in water prior to analysis and stored at   80 �C. A 
1 mM Tris (pH 8) buffer solution for the bioassay was made in Milli-Q 
water and its pH was checked at room temperature. After preparation, 
the buffer was stored at 4 �C until use. Cresol red and fluorescein were 
from Sigma-Aldrich. The 5 mM cresol red stock solution was prepared in 
methanol and stored at   20 �C. The 1 mM fluorescein stock solution was 
prepared in DMSO and kept at   80 �C. Triton-X-100 was purchased 
from Thermo Scientific (Landsmeer, Netherlands) and a stock solution of 
170 mM was prepared in Milli-Q water and stored at   20 �C. Phos-
phatidylcholine from soy beans was purchased from Sigma-Aldrich of 
which a stock solution of 20 mg/mL was prepared in methanol and kept 
at   20 �C. Varespladib was dissolved in DMSO (�99.9%, Sigma-Aldrich, 
Zwijndrecht, The Netherlands) and stored at   20 �C. 
2.2. PLA2 assay using cresol red as pH indicator 
Pre-prepared 1.0 mM TRIS buffer solution was used at room tem-
perature and pH 8.0. The assay was performed with all other reagents at 
room temperature, which is crucial due to the pH dependence of the 
assay. For best performance the assay reagent mix was freshly prepared 
in a 50 mL PP Centrifuge tube (Corning Life Sciences B.V., Amsterdam, 
The Netherlands). The mix contained NaCl (75 mM), KCl (75 mM), 
CaCl2 (7.5 mM), Cresol Red (0.037 mM), Triton-X-100 (0.66 mM) and 
phosphatidylcholine (0.66 mM) in 1.0 mM Tris (pH 8.0). The salts were 
added as dry compounds (after accurate weighing), whereas for the 
other constituents, accurate volumes of the stock-solutions (Section 2.1) 
were used. Triton-X-100 is needed to increase the solubility of the sub-
strate, improving the interaction between PLA2 and phosphatidylcho-
line. Direct addition of Triton-X-100 resulted in homogeneity problems 
and unsatisfactory assay performances. Therefore, the use of a pre- 
prepared stock solution of Triton-X-100 (170 mM) was used. The 
phosphatidylcholine solution was added last, as it slowly degrades upon 
contact with water. Prior to addition of phosphatidylcholine, the pH of 
the total solution was always checked and, if needed, adjusted to pH 8.0. 
The buffer capacity of the assay solution was low in order to allow 
Table 1 
List of analyzed snake venoms and their abbreviations as used in this study.  
Snake venom Origin Abbreviation 
Bothrops asper Costa Rica BA 
Echis carinatus Indiaa EC 
Echis coloratus Egypt ECO 
Echis ocellatus Nigeria EO 
Oxyuranus scutellatus Australia OS 
Daboia russelii russelii Sri Lanka DRR  
a Note that the Indian E. carinatus venom was collected from a single specimen 
that was inadvertently imported to the UK via a boat shipment of stone, and then 
rehoused at LSTM on the request of the UK RSPCA. 
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measurement of a pH drop as result of PLA2 activity. The assay was 
initiated by robotically pipetting 40 μL of the final assay reagent mix into 
each plate well containing either vacuum centrifuge-dried snake venom 
fractions or 10 μL of test solution, such as Varespladib (diluted in assay 
mixture to the required concentrations) used for assay development. In 
the latter case, concentrations of the assay mix constituents were 
adjusted to match the final assay concentrations stated above. The plate 
was placed in the plate reader within 5 min after pipetting, and the plate 
reader was thermostated at 25 �C. The absorbance of each well content 
was measured at 572 nm with a Thermo Fisher Scientific Laboratory 
Varioskan™ LUX Multimode Microplate Reader using SkanIt 4.1 
(Landsmeer, Netherlands). Measurements were performed in one kinetic 
loop with a total measurement time of 40 min. Two data-processing 
options in the SkanIt 4.1 software were used to determine PLA2 activ-
ity from the measured kinetic curves: (1) slope of a reading range (for 
well plates holding venom fractions), and (2) average rate in time per 
well (during assay development). For the latter, one measurement data 
point was plotted every 10 min over the total measuring curve. For 
constructing bioassay chromatograms of snake venoms, for each well 
the value resulting from the processed assay data was plotted against the 
LC elution time corresponding to the well. 
2.3. PLA2 assay using fluorescein as pH indicator 
In this PLA2 activity assay fluorescein is used as a fluorescent pH 
indicator in black 384-well, F-shape microplates (Greiner Bio One, 
Alphen aan den Rijn, the Netherlands). A decrease in assay pH causes a 
decrease of fluorescence intensity. Concentrations and preparation of 
the assay reagents and mix were the same as for the colorimetric assay 
(Section 2.2), but no Cresol Red was added. Instead, fluorescein was 
present at a final concentration of 1 μM. The assay was started by using 
the same procedure as stated in Section 2.2. The plate reader tempera-
ture was set at 25 �C and of each well fluorescence was measured using 
an excitation wavelength of 488 nm and an emission wavelength of 520 
nm in the Varioskan™ LUX Multimode Microplate Reader. Measure-
ments were performed in one kinetic loop with a total measurement time 
of 40 min. The bioassay data were presented as bioassay chromatograms 
when used for snake venom screening. 
The cleaning procedure of the robotic pipetting machine is as re-
ported previously in Still et al. (2017). For typical kinetic curve results 
obtained when running both PLA2 assay formats with venoms high in 
PLA2 abundance, the reader is referred to supporting information S1. 
The difference in curve slopes allows for the reconstruction of bioac-
tivity chromatograms (more details in Section 3.3). 
2.4. Instrumental setup for venom fractionation 
For high-resolution fractionation of snake venoms, the analytical 
system previously described by Still et al. (2017) and by Mladic et al. 
(2016) was used. Samples were injected with a Shimadzu SIL-30 A C 
auto sampler and LC separation was performed with a Shimadzu LC 
system controlled by Lab Solutions software. Gradient LC was performed 
using two Shimadzu LC-30AD pumps (A and B) operated at a total flow 
rate of 0.5 mL/min. Mobile phase A was water–ACN–FA (98:2:0.1, 
v/v/v) and mobile phase B was water–ACN–FA (2:98:0.1, v/v/v). The 
gradient was as follows: 0%–50% B (20 min), 50%–90% B (4 min), 90% 
B (5 min), 90%–0% B (1 min), 0% B (10 min). A 150 � 4.6 mm ID 
analytical column packed with Xbridge™ BEH300 reversed-phase C18 
material (5 μm) was used for separations and was maintained at 37 �C in 
a Shimadzu CTD-30 A column oven. The column effluent was split in a 
1:9 ratio using a low-dead-volume flow splitter. The flow of 0.05 
mL/min was either directed to waste or led to a high-resolution time--
of-flight (TOF) mass spectrometer for compound identification. During 
assay and method development, no MS data was acquired. The flow of 
0.45 mL/min was led to either a Gilson 235 robot programmed as 
fractionation device or a FractioMate™ fractionator (SPARK-Holland & 
VU, Netherlands, Emmen & Amsterdam) each providing fractions (6 
s/well) onto clear or black 384-well plates. Fractionation was controlled 
by employing in-house written Ariadne software or FractioMator soft-
ware (Spark-Holland & VU), respectively. The plates with fractions were 
vacuum centrifuged to dryness at room temperature using a Christ 
Rotational Vacuum Concentrator RVC 2–33 CD plus (Salm en Kipp, 
Breukelen, the Netherlands) with a cooling trap at   80 �C, and then 
stored at   80 �C. 
3. Results and discussion 
This research focused on the development and optimization of 
enzymatic PLA2 activity assays suitable for application in the nano-
fractionation platform to allow profiling of venom fractions. For this, 
these assays should be sensitive, rapid, robust, and applicable to small 
LC fractions (collected in 384-well plate format). PLA2 catalyzes the 
hydrolysis of ester bonds of glycerophospholipids at position sn-2. PLA2 
activity assaying can be based on the accompanying acidification of the 
reaction mixture caused by the formed free fatty acids during phos-
phatidylcholine hydrolysis. In presence of pH indicators, activity will 
cause measurable color changes. The use of bromothymol blue in the 
required miniaturized assay was considered for use in this study, how-
ever, (i) the literature reports this pH indicator to inhibit phospholipase 
subunits (Price, 2007), while pilot experiments using bromothymol blue 
for assaying venoms showed highly varying and non-repeatable results. 
Specifically, our pilot results appeared unrelated to PLA2 hydrolysis of 
phosphatidylcholine, and therefore bromothymol blue was not consid-
ered to be suitable for our purposes. Instead, we developed two assays 
suitable for 384-well format using phosphatidylcholine as a substrate, 
with either cresol red (CR) as a color pH indicator or fluorescein as a 
fluorescent pH indicator. 
3.1. PLA2 activity assay based on cresol red 
3.1.1. Assay optimization 
Going from pH 8.8 to 7.0, protonation of the pH indicator cresol red 
results in a color change from red to yellow. When cresol red is added to 
the assay reagent mixture, PLA2 activity can be detected as a decrease in 
absorbance at 572 nm (de Araújo and Radvanyi, 1987; Sutto-Ortiz et al., 
2017). The pH of the assay solution was first adjusted to 8.0 in order to 
allow sensitive detection of the pH shift. Optimal conditions were 
studied and achieved in several optimization steps, as described below. 
More detailed information and results on the development of the cresol 
red-based PLA2 activity assay are provided in the supporting informa-
tion S2 and S3. 
The optimal concentrations for cresol red and the substrate phos-
phatidylcholine were studied by performing serial dilution experiments. 
Daboia russelii russelii (DRR) snake venom, which is known for its rela-
tively high content of svPLA2, was used as a test venom for assay opti-
mization at a concentration of 12.5 μg/mL (Haney et al., 2019). Fig. 1 
shows time-course absorbance measurements in a cuvette using opti-
mized assay conditions and DRR venom. The color change of cresol red 
over time is observed as an increasing absorbance at 430 nm and a 
decreasing absorbance at 570 nm. As the absolute change is most sub-
stantial at 570 nm, this wavelength was used for the readout of the cresol 
red-based PLA2 assay. Higher concentrations of cresol red resulted in 
more intense red coloring of the assay mixture, detected as a higher 
absorbance at 572 nm at the start of the measurement (Figure S2). The 
optimal cresol red concentration was found to be 37 μM. Increasing the 
concentration of phosphatidylcholine resulted in an increased acidifi-
cation of the assay mixture upon assay progression when svPLA2s were 
present. The optimal substrate concentration was determined to be 0.66 
mM. Concentrations of 0.66 mM and 37 μM for phosphatidylcholine and 
cresol red, respectively, were used in all subsequent experiments. 
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3.1.2. Assay evaluation 
The optimized assay was evaluated for sensitivity and limit of 
detection (LOD) by analyzing different concentrations of DRR snake 
venom. 
The concentration-response plot for svPLA2 activity was assessed by 
analyzing serial dilutions of DRR venom in water (freeze-dried after 
addition to the wells) with final assay concentrations of 50, 25, 12.5, 6.3 
and 3.2 μg/mL (Fig. 2). 
The starting steepness of the declining curve is correlated to the DRR 
venom concentration and thus the overall activity of svPLA2s present in 
the assay mixture. Note that the starting point of the kinetic measure-
ment is the moment the plate reader measurement is initiated and thus 
does not represent the real starting point, which is the moment the assay 
mix is pipetted to the venom. As can be seen, increasing DRR concen-
trations resulted in faster declines in absorbance over time (Fig. 2). Also, 
the higher the concentration of DRR the lower the absorbance of the first 
measured point due to the initial faster enzymatic conversion rates. 
Therefore, after pipetting the assay mix to a well plate, the assay readout 
was started directly. 
The assay specificity, i.e. determining whether the assay reflects the 
action of PLA2s as the cause of the detected acidification, was performed 
by analyzing DRR venom in presence of the PLA2 inhibitor varespladib. 
A recent study by Lewin et al. demonstrated methyl-varespladib and 
varespladib to reduce venom PLA2-induced in vivo pathologies (Lewin 
et al., 2016). These compounds were shown to be potent inhibitors for a 
multitude of svPLA2s in vitro. An IC50 value of 0.96 μM � 0.04 μM was 
determined for varespladib (Lewin et al., 2016). As varespladib is a 
broad-range (non-specific) PLA2 inhibitor, it was anticipated to be able 
to inhibit the majority of svPLA2s present in a venom and as such 
concentration-dependently reduce the hydrolysis rate of phosphatidyl-
choline in the assay. The effect of the concentration of varespladib on the 
activity of DRR (final assay concentration, 12.5 μg/mL) was determined 
using serial dilutions of varespladib in Tris buffer (1 mM; pH 8; 10 
μL/well) with final concentrations of 20, 2, 0.002, and 0 μM (Fig. 3). 
When increasing concentrations of varespladib were added to the 
assay mixture, a concentration-dependent decrease in PLA2 activity was 
observed visible as a decrease in steepness of the curves. Even though 
the PLA2 activity was not fully inhibited within this concentration series, 
these results clearly show that the enzymatic acidification of the 
bioassay mixture was dose-dependently affected and almost full inhi-
bition was reached at the highest concentration varespladib tested. In 
the blank measurement, a slight decrease in absorbance was observed 
due to non-enzymatic (chemical) hydrolysis of phosphatidylcholine. 
Fig. 1. Absorbance spectra obtained during progression of the cresol red-based 
PLA2 activity assay. Conditions: phosphatidylcholine concentration, 0.66 mM; 
cresol red concentration, 37 μM; DRR venom concentration, 12.2 μg/mL. (For 
interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
Fig. 2. Kinetic absorbance measurements obtained of the cresol red based PLA2 
assay. Concentrations of phosphatidylcholine and cresol red were 0.66 mM and 
37 μM, respectively. Assay was performed in presence of a DRR concentration 
series with final assay concentrations of 50 μg/mL, 25 μg/mL, 12.5 μg/mL, 6.3 
μg/mL and 3.2 μg/mL (visualized from bottom to top). The absorbance was set 
at 570 nm. Each curve represents the mean of two measurements and the error 
bars represent SEMs. 
Fig. 3. Kinetic absorbance measurements obtained for assessing the inhibitory 
effect of the PLA2 inhibitor varespladib on the cresol red based PLA2 assay. 
Concentrations of phosphatidylcholine, cresol red, and DRR were 0.66 mM and 
37 μM, and 12.5 μg/mL, respectively. Assay was performed in presence of 
varespladib with final concentrations of 20, 2, 0.002, and 0 μM. The absorbance 
was set at 570 nm. Each curve represents the mean of three measurements and 
the error bars represent SEMs. 
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3.2. PLA2 assay based on fluorescein 
3.2.1. Assay development 
The fluorescence quantum yield of fluorescein is pH dependent, 
being highest at around pH 8. Its fluorescence decreases in the presence 
of lowered pH, which is the detection principle of the fluorescence assay 
format. Below pH 6 the emission starts to get weak, and becomes un-
detectable at very acidic conditions (Doughty, 2010; Martin and 
Lindqvist, 1975). For this assay a Tris buffer of pH 8 was chosen (as for 
cresol red) and the decrease of fluorescence intensity of fluorescein was 
monitored as result of PLA2 activity causing a drop in pH (Doughty, 
2010; Martin and Lindqvist, 1975). Additional information and results 
on the optimization of the fluorescein-based PLA2 activity assay is pro-
vided in Section S4 of the supporting information. Different fluorescein 
concentrations were tested (final concentrations: 0.2, 0.5, 1.0, and 5.0 
μM). The same phosphatidylcholine concentration as for the cresol 
red-based assay was used assuming the substrate concentration to be 
independent of the pH indicator used. Increasing the fluorescein con-
centration yielded more intense fluorescence signals at the start of a 
measurement (see Figure S4 in the supporting information). The optimal 
fluorescein concentration was determined to be 1 μM, providing optimal 
signal-to-noise ratios while achieving acceptable assay repeatability. 
Concentrations of 1 μM fluorescein and 0.66 mM phosphatidylcholine 
were used for all subsequent experiments. 
3.2.2. Fluorescein PLA2 assay evaluation 
The optimized fluorescein-based assay was further evaluated for 
sensitivity and LOD. DRR concentrations of 12.2, 6.1, 3.0, 1.6, 0.8, and 
0 μg/mL in Tris buffer (1 mM; pH 8; 10 μL/well) were analyzed (Fig. 4). 
The specificity was again tested by performing the activity assay with 
DRR in presence of different concentrations of varespladib. 
The DRR serial dilutions were added to different wells and then 
vacuum centrifuge dried prior to assay pipetting to avoid undesired 
dilution effects. As with the previous assay, the starting point of the 
kinetic measurement is the moment the plate reader measurement is 
initiated and as such thus not the real starting point, which is the 
moment the assay mix is pipetted to the venom. Therefore, after 
pipetting the assay mix to a well plate, the assay readout was started as 
soon as possible. Increased DRR concentrations resulted in increased 
progression of the svPLA2s enzymatic activity visible as declined fluo-
rescent intensities observed at the first measurement point of the curves. 
The last measurement point for the two highest DRR concentrations 
tested (12.2 μg/mL and 6.1 μg/mL) almost overlapped, indicating a 
smaller assay window for the fluorescein-based assay as compared to the 
cresol red assay when performing an end-point measurement. In the 
latter, a concentration of 50 μg/mL compares to the increase in assay 
progression of the svPLA2 enzymatic activity seen for 12.2 μg/mL in the 
fluorescein assay. The results thus also show that the fluorescein assay 
was more sensitive than the cresol red assay for DRR venom. With this 
assay, clear hydrolysis was already observed within 10 min at a DRR 
concentration of 1.6 μg/mL. In the fluorescein assay, a concentration of 
0.8 μg/mL DRR still gave a measurable effect after 40 min. 
The fluorescein-based assay was then evaluated for specificity for 
PLA2 activity by measuring a concentration series of the PLA2 inhibitor 
varespladib. The effect of the concentration of varespladib on the ac-
tivity of DRR was determined for two final concentrations of DRR snake 
venom (12.2 and 1.6 μg/mL; Figs. 5 and 6 respectively). The reason we 
tested an additional snake venom concentration of 1.6 μg/mL in this 
experiment was because of the relatively rapid hydrolysis rate upon 
assay initiation when testing 12.2 μg/mL. Hence we wanted to test and 
show the effect of using a lower snake venom concentration on assay 
performance and on the ability of varespladib to neutralize snake venom 
PLA2s. Serial dilutions of varespladib in Tris buffer (1 mM; pH 8; 10 μL/ 
well) with final concentrations of 50, 5.0, 0.5, 0.05, and 0 μM were 
tested (Figs. 5 and 6). Varespladib was found to inhibit the PLA2 activity 
in a concentration-dependent manner, with full inhibition observed at a 
concentration of 5 μM for the 1.6 μg/mL DRR experiment and 50 μM for 
the 12.2 μg/mL DRR experiment. As also observed with the cresol red 
assay, the fluorescein-based assay thus shows specificity towards enzy-
matic PLA2 activity. 
To summarize the two approaches compared here, the PLA2 assay 
using cresol red facilitates measuring a wider range of PLA2 concen-
trations in comparison with the fluorescein-based assay. However, the 
latter assay is more sensitive. 
Fig. 4. Kinetic fluorescence measurements obtained for the fluorescein based 
PLA2 assay. Concentrations of phosphatidylcholine and fluorescein were 0.66 
mM and 1 μM, respectively. DRR concentrations tested: 12.2, 6.1, 3.2, 1.6, and 
0.8 μg/mL. Fluorescence was measured using an excitation wavelength of 488 
nm and an emission wavelength of 520 nm. Each curve represents the mean of 
three measurements and the error bars represent SEMs. 
Fig. 5. Kinetic fluorescence measurements obtained for assessing the inhibitory 
effect of the PLA2 inhibitor varespladib on the fluorescein based PLA2 assay. 
Concentrations of phosphatidylcholine, fluorescein, and DRR were 0.66 mM 
and 1 μM, and 12.2 μg/mL, respectively. The assay was performed in presence 
of varespladib with final concentrations of 50, 5.0, 0.5, 0.05, and 0 μM. Fluo-
rescence was measured using an excitation wavelength of 488 nm and an 
emission wavelength of 520 nm. Each curve represents the mean of two mea-
surements and the error bars represent SEMs. 
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3.3. Coupling of the two PLA2 assay formats with nanofractionation 
analytics 
Finally, the two developed assays were incorporated into the nano-
fractionation analytics platform. This allowed for obtaining enzymati-
cally bioactive PLA2 profiles of snake venoms after chromatographic 
separation. 
SvPLA2s are derived from members of the serine PLA2 (sPLA2) fam-
ily, which are found in mammals and other vertebrates. It is said that the 
genes expressing svPLA2s have undergone gene duplication and accel-
erated evolution over evolutionary time, which has resulted in struc-
tural, functional, and expressional level variations of svPLA2s isoforms 
(Calvete, 2016, 2019). As such, many snake venoms are known to 
contain a number of different svPLA2 isoforms. The presence of these 
isoforms, and their abundances, can thus vary greatly according to 
species, but also according to, for example, population, age and sex of a 
snake, and (prey) ecology (Gibbs and Rossiter, 2008; TSAI et al., 2004; 
Tsai et al., 2007). The generic svPLA2 tertiary structure, contains seven 
disulfide bridges. This means that for an enzyme, svPLA2s are considered 
to be rather stable and are therefore relatively resistant to heat, organic 
solvents, and acidic conditions (Lewin et al., 2016). These properties, 
their high abundance in many snake venoms, and their relatively low 
molecular weight (~13–15 kDa) is advantageous for their intact iso-
lation/fractionation using reversed phase liquid chromatography 
(RPLC) thereby allowing subsequent characterization and bioactivity 
profiling(Gasanov, 2014; Guti�errez and Lomonte, 2013). 
The nanofractionation analytics platform connects chromatographic 
separations of venoms with UV data collection, optionally mass spec-
trometry, and high-resolution fractionation on well plates followed by 
bioassaying. This platform for screening snake venoms has been 
described earlier by others, including for example Mladic et al. (2016) 
and Still et al. (2017) for other assay formats. In this study, snake 
venoms were separated using RP-LC with a post column split directing 
90% of the effluent to a high-resolution fraction collector (e.g. the 
FractioMate) and 10% to UV and optionally MS. After fraction collection 
in 384-well plates, the plates were vacuum centrifuged to remove sol-
vents after which one of the two PLA2 bioassays was performed. After 
bioassaying, reconstructed bioassay chromatograms were plotted which 
could then be correlated to UV and MS traces in an effort to identify the 
enzymatically active svPLA2s. As one of the important aspects of this 
analytical platform is the ability to perform offline assays, the venom 
toxins have to survive the analytical separation without denaturation. In 
addition, compatibility with sensitive MS, gives limited options with 
regards to eluent substituents. Making use of formic acid (FA), meant 
that many venom toxin enzymes remain intact and retain their activity 
during separation. However, concessions are thus made in separation 
resolution and peak capacity, as closely eluting venom toxins are not 
fully separated from each other during LC-separation in the elution 
time-frame currently used. Bioactive peaks in the bioactivity chro-
matograms were found often closely eluting or overlapping. This implies 
that it is difficult to determine the individual contribution to an observed 
bioactivity of multiple closely eluting toxins. Currently, work is ongoing 
on investigating different MS compatible separations and eluent com-
positions to improve resolution and peak capacity of eluting venom 
toxins in their native state while retaining ESI-MS compatibility and 
sensitivity. This research is ongoing and beyond the scope of this study. 
Venom of six snake species were screened for svPLA2 activity using 
the cresol red PLA2 assay and venoms of one snake was screened using 
the fluorescein-based PLA2 assay. The results obtained for the cresol red 
based assay are shown in Fig. 7. Each experiment was performed in 
duplicate and both the LC-UV spectral data as well as the chromato-
graphic bioactivity profiles (representing the mean of three measure-
ments) are provided. The bioassay chromatograms were constructed by 
plotting the calculated slopes of each measured svPLA2 activity curve of 
each well against fractionation time. As 6-sec fractions were collected, 
high resolution reconstructed bioassay chromatograms were obtained. 
svPLA2 activity is detected as an increase in the slopes of the kinetic 
measurements and is svPLA2 concentration-dependent (e.g. as shown in 
Fig. 3). The enzymatic activities of eluted svPLA2s are therefore visible 
in the reconstructed bioassay chromatograms as positive peaks. Each 
venom analyzed was found to have its own characteristic fingerprint or 
signature-like LC-UV chromatogram with corresponding bioactivity 
chromatogram profile. The depicted 220 nm UV-VIS traces give the most 
sensitive results of all recorded UV traces. However, despite being the 
most sensitive, one drawback using this wavelength is the baseline drift 
visible upon chromatographic gradient progression, due to UV absor-
bance of organic modifier impurities. The most important function of the 
given LC-UV-traces is alignment between bioassay chromatograms, post 
separation MS analysis, and the possibility to match our chromatog-
raphy results of those obtained in other labs. The results displayed in 
Fig. 7 show that the enzymatically active peaks for all venoms analyzed 
eluted in the 15 to 25-min time frame. Later eluting (non-enzymatically- 
active) peaks may, although not likely for the relatively stable svPLA2s, 
be denatured svPLA2s (due to the high organic solvent (i.e. acetonitrile) 
concentration during elution). As can be seen from the chromatographic 
PLA2 activity data, all the snake venoms analyzed show positive svPLA2 
activity peaks, which indicates that all venoms profiled contain at least 
one, but in most cases multiple, svPLA2s. 
With the fluorescein-based PLA2 assay, Bothrops asper was profiled 
(Fig. 8). For the fluorescein-based assay it was observed that larger assay 
windows in combination with lower fluctuation in the baselines were 
obtained as compared to the cresol red based assay, visualized as posi-
tive bioactivity peaks in the fluorescence bioassay chromatograms. For 
Bothrops asper venom, several svPLA2 bioactivities are clearly observed 
and, when compared to the results obtained from the cresol red assay, 
additional bioactivities were visualized due to the higher sensitivity of 
the fluorescein-based assay. After the first set of closely co-eluting 
svPLA2s observed in both assays (between ~17 and 19 min), these 
additional svPLA2 activities are observed after the first broad peak and 
eluted as one sharp peak followed by two non-baseline separated 
bioactivity peaks. 
It has to be noted that for both assays, not all positive peaks observed 
need to correspond with svPLA2 activities. Although not expected, other 
toxins in venoms could have enzymatic activities directly or indirectly 
resulting in acidification or basification of the assay medium. As the 
Fig. 6. Kinetic fluorescence measurements obtained for assessing the inhibitory 
effect of the PLA2 inhibitor varespladib on the fluorescein based PLA2 assay. 
Concentrations of phosphatidylcholine, fluorescein, and DRR were 0.66 mM 
and 1 μM, and 1.6 μg/mL, respectively. The assay was performed in presence of 
varespladib with final concentrations of 50, 5.0, 0.5, 0.05, and 0 μM. Fluores-
cence was measured using an excitation wavelength of 488 nm and an emission 
wavelength of 520 nm. Each curve represents the mean of two measurements 
and the error bars represent SEMs. 
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Fig. 7. UV-chromatograms (lower superimposed chromatograms per figure) and corresponding cresol red assay-PLA2 reconstructed bioassay chromatograms (upper 
superimposed chromatograms per figure) obtained from RP-LC separated snake venoms. Snake venoms measured: (a) Bothrops asper; (b) Daboia russelii russelii; (c) 
Echis coloratus; (d) Echis ocellatus; (e) Oxyuranus scutellatus; (f) Echis carinatus. Experimental conditions: Snake venom concentrations injected were 1 mg/mL with an 
injection volume of 50 μL. A UV-DAD detector measured the spectrum between 200 and 300 nm of which 220 nm (blue) is plotted in the figures. For correlating 
bioactivity peaks to tentative toxin identification, the reader is referred to section 3.4 (only for the venoms of Bothrops asper, Daboia russelii russelii, and Echis ocellatus 
this tentative toxin identification was performed). Green dotted lines indicate tentatively identified svPLA2s. (For interpretation of the references to color in this 
figure legend, the reader is referred to the Web version of this article.) 
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assay mixture’s color change is dependent on the pH indicator and 
therefore the pH of the mixture, compounds with acidic and/or basic 
functional groups present in high concentrations could potentially 
chemically modulate the assay pH and as such result in negative or 
positive peaks. Although in general this is not likely to occur, this might 
be the outcome of the negative peak observed in the bioactivity chro-
matogram of Echis coloratus (Fig. 7C). This negative activity might have 
resulted from a compound having a basifying effect on the assay mix-
ture’s pH. In this specific case it is not expected to have resulted from an 
activity linked to enzymatic PLA2 activity. With the used concentrations 
of the detergent triton-X-100 and the substrate phosphatidylcholine in 
our assay, we assume to be working in the intermediate stage of phos-
pholipid solubilization and thus assume that our phospholipid substrate 
is present in both detergent-saturated form and as mixed micelles (fully 
solubilized) (De la Maza and Parra, 1994; Kragh-Hansen et al., 1998). It 
is known that svPLA2s can display a change in activity (mostly an in-
crease) when enzymatically converting higher-ordered lipid aggregate 
substrates. Some svPLA2s may show low activity for the phospholipid 
substrate used in this study (Cho et al., 1988). 
3.4. Correlation of enzymatically active peaks with MS and proteomics 
data for toxin identification 
From literature and the database Uniprot (https://www.uniprot. 
org/) (“https://www.uniprot.org/,” n. d.) it was found that all snake 
venoms profiled in this study have multiple known svPLA2s. Table 2 
displays a summarized list of the number of svPLA2s found in the liter-
ature and from the Uniprot database. The table also lists the number of 
PLA2-linked enzymatic activities found for both assays developed and 
applied in this study after nanofractionation of the profiled venoms. 
From the overview it is evident that for most snake venoms analyzed, 
more individual svPLA2 isoforms are reported in the literature and 
Uniprot, when compared to the number of individual positive peaks 
found per venom in this study. The reason for this is likely as follows: 
firstly, snake venoms of the same species, but from different geograph-
ical origins, often have different venom compositions implying that not 
all svPLA2s necessarily will be expressed at significant levels in each 
venom. Secondly, the chromatographic overlap of svPLA2 isoforms 
resulting from chromatographic co-elution of (especially structurally 
similar) svPLA2s results in overlapping bioactivity peaks for which 
multiple svPLA2 isoforms can be assigned to. This was also clearly shown 
in other studies by Still et al. (2017) and Slagboom et al. (2020) In 
addition, although highly unlikely due to their generic stability to the LC 
solvents used in this study, some svPLA2s in Uniprot could be present in 
a given venom but showed reduced catalytic activity or have lost their 
activity due to denaturation in our experiments. Furthermore, some 
sub-classes of svPLA2s have lost their enzymatic activity (among which 
are neurotoxic svPLA2s and lysine/serine 49 svPLA2s) and/or only have 
minor enzymatic activity as compared to their other biological functions 
which can include specific target-binding, chaperoning, and/or 
membrane-disrupting functions (Gopalakrishnakone and Calvete, 
2016). 
Accurate mass measurements and proteomics data of the toxins 
present in several snake venoms included in this study were recently 
reported by Slagboom et al. (2020) They used the same 
LC-nanofractionation platform in combination with parallel acquired 
MS data and profiled coagulopathic activity followed by proteomic 
characterization of the active coagulopathic compounds. The following 
three snake venoms analyzed by Slagboom et al. were also investigated 
in this study: Bothrops asper, Echis ocellatus, and Daboia russelii russelii. 
The MS and proteomics data of Slagboom et al. was used here for cor-
relation of svPLA2 activity to hypothetical toxin identification in order to 
determine platform applicability for svPLA2 profiling of snake venoms 
towards identification of the bioactives. Slagboom et al. profiled and 
tentatively identified venom toxins that exhibited coagulopathic activity 
and thus might not match svPLA2 activities measured this study. Several 
positive signals in our svPLA2 assays could, however, be correlated to 
identified svPLA2s by Slagboom et al., as they fell within the same 
retention timeframes (note that the same chromatographic conditions 
were used in both studies). In Bothrops asper, Slagboom et al. found four 
svPLA2s with m/z-values of 1378.369710þ, 1373.368810þ, 
1267.790611þ, and 1164.888112þ. Combining the fluorescein and cresol 
red PLA2 assay data of Bothrops asper measured this study after nano-
fractionation resulted in correlation of most activities with the MS and 
proteomics data from Slagboom et al. The first two eluting svPLA2s with 
m/z-values of 1378.369710þ and 1373.368810þ co-eluted in the chro-
matogram and therefore could not be differentiated. Two additional 
activities were detected in the fluorescent PLA2 assay, which were not 
measured by Slagboom et al. (who only did MS and proteomics analysis 
on coagulopathic venom toxins). Two masses within the svPLA2 mass 
range were identified by Slagboom et al. for Daboia russelii russelii venom 
and one for Echis ocellatus venom. For both venoms, the identified 
m/z-values could be correlated to the svPLA2 bioactivity peaks falling 
within the same retention timeframe and were 1511.69629þ and 
1518.59469þ for Daboia russelii russelii venom, and 1537.04899þ for 
Echis ocellatus venom. In Figs. 7 and 8, the tentatively identified svPLA2s 
correlating to bioactivity peaks are indicated with green marker arrows 
pointing to their respective bioactivity peaks for Bothrops asper, Echis 
ocellatus, and Daboia russelii russelii venoms. 
4. Conclusion 
The PLA2 assays developed herein were demonstrated to be sensitive 
and robust and were successfully coupled to nanofractionation analytics 
to analyze svPLA2 activity of separated venom toxins. The PLA2 assay 
using cresol red was found to have the largest assay window, i.e. being 
Fig. 8. UV-chromatogram (lower superimposed chromatogram) and corre-
sponding fluorescein assay-PLA2 reconstructed bioassay chromatograms (upper 
superimposed chromatogram) obtained from RP-LC separated snake venoms. 
Snake venom measured: Bothrops asper; Experimental conditions: Snake venom 
concentrations injected were 1 mg/mL with an injection volume of 50 μL. A UV- 
DAD detector measured the spectrum between 200 and 300 nm of which 220 
nm (blue) is plotted in the figure. For correlating bioactivity peaks to tentative 
toxin identification, the reader is referred to section 3.4. Green dotted lines 
indicate tentatively identified svPLA2s. (For interpretation of the references to 
color in this figure legend, the reader is referred to the Web version of 
this article.) 
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Table 2 
Overview of numbers of svPLA2 isoforms identified by different research groups and placed in the Uniprot database, numbers of svPLA2 isoforms identified by 
Slagboom et al., and detected number of enzymatically actives in the developed cresol red and/or fluorescein-based PLA2 assays described in this study. n.d. means no 
data available.  
Snake species Uniprot database svPLA2 isoforms Masses of svPLA2s identified 
by Slagboom et al. 
svPLA2 bioactivities found in 
cresol red PLA2 assay 
svPLA2 bioactivities found in 
fluorescein PLA2 assay 
Bothrops asper 6 
11. P24605 (PA2H2_BOTAS) L 137, M: 15,509 Da 
2. P20474 (PA2B3_BOTAS) L: 138, M: 15,751 Da 
3. P86389 (PA2A2_BOTAS) L: 124, M: 14,194 Da 
4. P0C616 (PA2HA_BOTAS) L: 137, M: 15.688 Da 
5. Q9PVE3 (PA2H3_BOTAS) L: 138, M: 15,559 Da 
6. Q9PRT7 (PA2H4_BOTAS) L: 23, M: 2512 Da 
(Fragment) 




1. P59071 (PA2B8_DABRR) L: 121, M: 13,611 Da 
2. A8CG86 (PA2A1_DABRR) L: 138, M: 15,3289 Da 
3. P84674 (PA2B5_DABRR) L: 121, M: 13,587 Da 
4. P81458 (PA2B_DABRR) L: 121, M: 13,626 Da 
5. A8CG89 (PA2B1_DABRR) L: 138, M: 15,864 Da 
6. A8CG90 (PA2B2_DABRR) L: 137, M: 15,461 Da 
7. C0HK16 (PA2BD_DABRR) L: 121, M: 13,612 Da 
8. P0DKX1 (PA2N_DABRR) L: 19, M: 2194 Da 
(Fragment) 
9. A8CG87 (PA2A2_DABRR) L: 138, M: 15,586 Da 
10. P86368 (PA2B3_DABRR) L: 121, M: 13,687 Da 
11. P86529 (PA21_DABRR) L: 17, M: 1955 Da 
12. Q2ES53 (Q2ES53_DABRR) L: 138, M: 15,865 Da 
13. Q2ES52 (Q2ES52_DABRR) L: 122, M: 13,441 Da 
14. Q2ES51 (Q2ES51_DABRR) L: 137, M: 15,123 Da 
15. A0A223PK47 (A0A223PK47_DABRR) L: 704, M: 
79,785 Da (Fragment) 
16. B3RFI6 (B3RFI6_DABRR) L: 138, M: 15,421 Da 
17. B3RFI8 (B3RFI8_DABRR) L: 137, M: 15,353 Da 
18. B3RFI7 (B3RFI7_DABRR) L: 138, M: 15,652 Da 
19. A0A223PK58 (A0A223PK58_DABRR) L: 792, M: 
87,179 Da (Fragment) 
20. A0A223PK40 (A0A223PK40_DABRR) L: 1,396, 
M: 160,882 Da (Fragment) 
2 n > 3 n.d. 
Echis coloratus 11 
1. P0DMT3 (PA2HS_ECHCO) L: 121, M: 13,706 Da 
2. Q910A0 (PA23_ECHCO) L: 138, M: 15,638 Da 
3. B5U6Y4 (PA2HS_ECHCO) L: 138, M: 15,634 Da 
4. Q90ZZ9 (PA21_ECHCO) L: 138, M: 15.770 Da 
5. A0A0A1WC82 (A0A0A1WC82_ECHCO) L: 137, M: 
15,595 Da 
6. A0A081DUB1 (A0A081DUB1_ECHCO) L: 151, 
M:16,855 Da 
7. A0A0A1WCG3 (A0A0A1WCG3_ECHCO) L: 138, M: 
15,674 Da 
8. A0A0A1WDQ3 (A0A0A1WDQ3_ECHCO) L: 155, 
M: 16,954 Da (Fragment) 
9. A0A0A1WDL6 (A0A0A1WDL6_ECHCO) L: 148, M: 
16,636 Da (Fragment) 
10. A0A0A1WC86 (A0A0A1WC86_ECHCO) L: 120, 
M: 13,353 Da (Fragment) 
11. A0A0A1WCW3 (A0A0A1WCW3_ECHCO) L: 79, 
M: 9265 Da (Fragment) 
n.d. 2–3 n.d. 
Echis ocellatus 2 
1. B5U6Y4 (PA2HS_ECHOC)L: 138, M: 15,634 Da 
2. P59171 (PA2A5_ECHOC) L: 138, M: 15,705 Da 




1. P00614 (PA2TA_OXYSC) L: 119, M: 13,829 Da 
2. Q45Z47 (PA22_OXYSC) L: 146, M: 16,104 Da 
3. P00615 (PA2TB_OXYSC) L: 145, M: 16,008 Da 
4. P00616 (PA2TG_OXYSC) L: 152, M 16,558 Da 
5. P0CG57 (PA2TC_OXYSC) L: 118, M: 13,313 Da 
6. Q4VRI5 (PA21_OXYSC) L: 154, M 16,898 Da 
7. Q7LZG2 (PA2T_OXYSC) L: 27, M 2901 Da 
(Fragment) 
8. P0DKT7 (PA2CA_OXYSA) L: 20, M: 2382 Da 
(Fragment) 
9. P0DKT9 (PA2CC_OXYSA) L: 40, M 4473 Da 
(Fragment) 
10. P0DKU0 (PA2CG_OXYSA) L: 30, M: 3388 Da 
(Fragment) 
11. P0DKT8 (PA2CB_OXYSA) L: 10, M 1178 Da 
0 2–5 n.d. 
(continued on next page) 
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able to detect a larger variation in PLA2 concentrations, while the 
fluorescein-based assay proved to be the most sensitive assay, thereby 
making both assays complementary to one another. When using C18 RP- 
LC with nanofractionation analytics for svPLA2 profiling of snake 
venoms, reproducible specific fingerprint-like separation profiles were 
obtained of which bioactive svPLA2s showed positive bioactivity peaks 
in the reconstructed bioactivity chromatograms. As many svPLA2s have 
similar primary sequences, and thus much structural resemblance, 
overlap of different bioactive svPLA2s by co-elution was expected and 
was indeed observed in this study. Prior accurate mass and proteomics 
data of some of the venoms used in this study was repurposed here for 
svPLA2 identification, and to assess assay and analytical platform per-
formance, resulting in bioactivity chromatograms with tentatively 
identified enzymatically active svPLA2s. We anticipate that our devel-
opment of new analytics for rapidly profiling svPLA2 activity will have 
utility for future research on snakebite pathologies caused by svPLA2 
toxins, and for the identification of novel inhibitory molecules capable 
of neutralizing svPLA2s for their future selection and translation into 
snakebite therapeutics. 
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